Talis BiomedicalTLIS
13F holders, Q2 2024 (June 30)At the end of Q2 2024, 18 institutions reported holding Talis Biomedical Corp. (TLIS) in their 13F filings, unchanged from Q1 2024. 2 opened new positions and 2 sold out. The largest holders were Baker Bros. Advisors LP ($4.4M), Greenlight Capital (DME Capital Management) ($1.3M) and BML Capital Management, LLC ($370K). 2 famous investors held it, including David Einhorn (0.1% of Greenlight Capital (DME Capital Management)'s portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Talis Biomedical Corp.
- CUSIP
- 87424L207
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $1K |
| Exits | 2 | $3K |
All 13F filers, Q1 2024 → Q2 2024: 4,290 shares bought and 7,322 shares sold, net −3,032 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Baker Bros. Advisors LP | 0.06% | No change | 508,323 | $4.4M |
| Greenlight Capital (DME Capital Management) | 0.06% | No change | 149,052 | $1.3M |
| BML Capital Management, LLC | 0.27% | No change | 42,743 | $370K |
| Vanguard Group Inc. | 0.00% | No change | 31,013 | $269K |
| Prelude Capital Management, LLC | 0.01% | No change | 14,928 | $129K |
| Geode Capital Management, LLC | 0.00% | Add +17.9% | 14,020 | $123K |
| Renaissance Technologies | 0.00% | Add +19.4% | 12,299 | $107K |
| Susquehanna International Group, LLP | 0.00% | Reduce -33.4% | 11,607 | $102K |
| BlackRock Inc. | 0.00% | Reduce -9.3% | 4,271 | $37K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -5.4% | 877 | $8K |
| Steward Partners Investment Advisory, LLC | 0.00% | New | 147 | $1K |
| Morgan Stanley | 0.00% | Reduce -86.3% | 87 | $754 |
| Osaic Holdings, Inc. | 0.00% | Reduce -31.1% | 84 | $727 |
| Larson Financial Group LLC | 0.00% | No change | 14 | $121 |
| Bank of America Corp. | 0.00% | New | 13 | $113 |
| UBS Group AG | 0.00% | Reduce -90.8% | 11 | $95 |
| JPMorgan Chase & Co. | 0.00% | No change | 3 | $26 |
| Qube Research & Technologies Ltd | 0.00% | No change | 2 | $18 |
"% of holder's portfolio" is TLIS's weight in each manager's 13F, not the share of Talis Biomedical Corp. the manager owns.